IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
1.420
-0.040 (-2.74%)
Jun 23, 2026, 9:30 AM EDT - Market open
IN8bio Employees
IN8bio had 18 employees as of March 31, 2026. The number of employees did not change compared to the same quarter last year.
Employees
18
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,054,444
Market Cap
13.98M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 18 | 0 | - |
| Dec 31, 2025 | 17 | -1 | -5.56% |
| Sep 30, 2025 | 17 | -1 | -5.56% |
| Jun 30, 2025 | 18 | -21 | -53.85% |
| Mar 31, 2025 | 18 | -16 | -47.06% |
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Sep 30, 2024 | 18 | -13 | -41.94% |
| Jun 30, 2024 | 39 | 10 | 34.48% |
| Mar 31, 2024 | 34 | 6 | 21.43% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Sep 30, 2023 | 31 | 5 | 19.23% |
| Jun 30, 2023 | 29 | 8 | 38.10% |
| Mar 31, 2023 | 28 | 7 | 33.33% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Sep 30, 2022 | 26 | 13 | 100.00% |
| Jun 30, 2022 | 21 | 7 | 50.00% |
| Mar 31, 2022 | 21 | 7 | 50.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Quince Therapeutics | 38 |
| BioLineRx | 24 |
| Citius Pharmaceuticals | 23 |
| Jasper Therapeutics | 22 |
| Atossa Therapeutics | 16 |
| BioVie | 13 |
| Cocrystal Pharma | 10 |
| Lexaria Bioscience | 7 |
INAB News
- 20 days ago - IN8bio Announces Publication in Nature Communications Highlighting Advances in Gamma-Delta T Cell Engineering and Combination Therapies - GlobeNewsWire
- 21 days ago - IN8bio Slides: Corporate presentation - Filings
- 21 days ago - IN8bio announces updated INB-200, INB-400 study data - TheFly
- 22 days ago - IN8bio Presents Updated Overall Survival Data Surpassing 19.5 Months for DeltEx DRI in Newly Diagnosed Glioblastoma at ASCO 2026 - GlobeNewsWire
- 4 weeks ago - IN8bio Transcript: R&D Day 2026 - Transcripts
- 4 weeks ago - IN8bio Slides: FY 2026 - Filings
- 5 weeks ago - IN8bio Registration statement: Registration filing - Filings
- 6 weeks ago - IN8bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - GlobeNewsWire